News/Events

Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study Tuesday, January 20th, 2015

Kinex Pharmaceuticals announced today that the first actinic keratosis patient has been dosed with KX2-391 ointment in Austin, Texas. Read more>

Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study Wednesday, December 24th, 2014

Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute. Read more>

Kinex Pharmaceuticals Appoints Chief Operating Officer Wednesday, December 17th, 2014

Kinex Pharmaceuticals announced today that Mr. Flint Besecker has been appointed Chief Operating Officer of the company. Mr. Besecker will have additional responsibility over Kinex’s emerging global operating platforms in addition to all corporate business matters reporting to Kinex’s Chief Executive Officer, Dr. Johnson Lau. Read more>

Hanmi Pharmaceuticals and Collaborative Partner Kinex Pharmaceuticals Announce Preliminary Results from a Phase I Clinical Study (HM-OTE-103) with Oratecan® in Patients with Advanced Cancer Wednesday, October 15th, 2014

Hanmi Pharmaceuticals and Collaborative Partner Kinex Pharmaceuticals announce today preliminary results from a Phase I Clinical Study of Oratecan – an oral form of the approved intravenously administered cancer drug irinotecan, with HM30181, a potent and selective, P-glycoprotein inhibitor of the gastro-intestinal tract. Read more>

Kinex Completes Acquisition of QuaDPharma Tuesday, September 9th, 2014

• Adds GLP and cGMP Capabilities to Kinex Platform
• Generates Opportunity to Execute Against Global Manufacturing Opportunities

Kinex Pharmaceuticals Inc. today announced that it has completed the acquisition of QuaDPharma, LLC., a Western New York based privately-held company specializing in pharmaceutical manufacturing, analytical and support services to the pharmaceutical and biotech industries. Financial terms of the transaction were not disclosed. Read more>